Prognostic factors for long-term survival identified in multivariate analysis
| . | OS . | P . | Relapse . | P . | Nonrelapse mortality . | P . |
|---|---|---|---|---|---|---|
| HR (95% CI) . | HR (95% CI) . | HR (95% CI) . | ||||
| ELN risk,* adverse vs favorable/INT | 3.68 (1.94-6.95) | <.001 | 2.84 (1.13-7.13) | .027 | ||
| Post-HCT VAF ≥0.2% | 3.07 (1.48-6.38) | .003 | 4.75 (2.00-11.29) | <.001 | ||
| Chronic GVHD, any grade | 0.10 (0.03-0.32) | <.001 | 4.40 (1.27-15.29) | .020 |
| . | OS . | P . | Relapse . | P . | Nonrelapse mortality . | P . |
|---|---|---|---|---|---|---|
| HR (95% CI) . | HR (95% CI) . | HR (95% CI) . | ||||
| ELN risk,* adverse vs favorable/INT | 3.68 (1.94-6.95) | <.001 | 2.84 (1.13-7.13) | .027 | ||
| Post-HCT VAF ≥0.2% | 3.07 (1.48-6.38) | .003 | 4.75 (2.00-11.29) | <.001 | ||
| Chronic GVHD, any grade | 0.10 (0.03-0.32) | <.001 | 4.40 (1.27-15.29) | .020 |
In multivariate analysis, VAF at day +21 post-HCT ≥0.2% and adverse risk according to the revised ELN recommendations were independent prognostic factor for worse relapse incidence and mortality. Chronic GVHD was an independent favorable prognostic factor for relapse incidence and worse prognostic factor for nonrelapse mortality
INT, intermediate. Other abbreviations are explained in Table 1.
Based on 2017 ELN recommendations from an international expert panel.40